Lineage Cell Therapeutics, Inc.
Lineage Cell Therapeutics, Inc.（LCTX）股东结构
基于 13F 申报与流通股数据，展示机构、内部人与公众持股结构；下方为前十大机构、机构动向与内部人交易。
SEC 13F · FMP · LCTX · 截至 2025年9月30日
股东结构概览
116
机构持有人数
▼ 16 vs Q2
$148.57M
机构持仓总市值
▲ $60.21M vs Q2
249.30M
总流通股
freeFloat 94.88%
87.92M
13F 申报持股数
▼ 9.86M vs Q2
机构持仓% = 13F 持股数 ÷ 总流通股。内部人% = 100 − 自由流通率。散户% = 自由流通率 − 机构%。数据来源：FMP /symbol-positions-summary + /shares-float + SEC EDGAR。
前10大机构持仓
LCTX 最大股东 · 机构持仓
Q3 2025 · SEC 13F
显示前 10 家
| 机构 | 持股数 | 占比 | 权重 | 市值 | 申报日 | 变动 |
|---|---|---|---|---|---|---|
BROADWOOD CAPITAL INC biological products, (no diagnostic substances) | 49.56M | 21.70% | 21.70% | $83.76B | Nov 14, 2025 | — held |
VANGUARD GROUP INC biological products, (no diagnostic substances) | 9.01M | 3.94% | 3.94% | $15.22B | Nov 7, 2025 | ▲ 524.1K |
RAFFLES ASSOCIATES LP biological products, (no diagnostic substances) | 5.39M | 2.36% | 2.36% | $9.11B | Nov 14, 2025 | ▼ 4.3K |
COMERICA BANK biological products, (no diagnostic substances) | 4.60M | 2.01% | 2.01% | $7.77B | Nov 14, 2025 | — held |
MILLENNIUM MANAGEMENT LLC biological products, (no diagnostic substances) | 2.68M | 1.17% | 1.17% | $4.53B | Nov 14, 2025 | ▲ 79.4K |
GEODE CAPITAL MANAGEMENT, LLC biological products, (no diagnostic substances) | 2.42M | 1.06% | 1.06% | $4.09B | Nov 12, 2025 | ▼ 11.9K |
BLACKROCK, INC. biological products, (no diagnostic substances) | 2.23M | 97.69% | 97.69% | $3.77B | Nov 12, 2025 | ▼ 30.0K |
RENAISSANCE TECHNOLOGIES LLC biological products, (no diagnostic substances) | 1.91M | 83.45% | 83.45% | $3.22B | Nov 13, 2025 | ▼ 66.7K |
DAUNTLESS INVESTMENT GROUP, LLC biological products, (no diagnostic substances) | 1.61M | 70.68% | 70.68% | $2.73B | Nov 14, 2025 | ▲ 408.2K |
MORGAN STANLEY biological products, (no diagnostic substances) | 1.01M | 44.07% | 44.07% | $1.70B | May 27, 2026 | ▲ 169.0K |
数据来源：SEC 13F 申报文件。变动标识：isNew / isSoldOut / changeInSharesNumber。
机构仓位变动
Q3 2025 对比上季度
Q3 2025
20
增持
+2.06M 股5
新建仓
首次建仓17
减持
−3.02M 股0
清仓
完全退出净股数变化（前50家）
962.4K
+2.06M / −3.02M
净新增持仓人
+8
新建 5 个 / 退出 0 个
基于前50家最大机构持仓统计，全市场实际数量可能不同。
内幕交易买卖情绪
LCTX 内幕交易记录
数据来源：SEC Form 4
近期内部人员净买入。 卖出可能源于预定的 10b5-1 计划，不代表负面展望。
6
买入笔数
4
卖出笔数
1.50
买卖比
$0M
卖出总金额
最近内幕交易记录
最近10条 · 仅普通股
| 姓名 · 职位 | 日期 | 类型 | 股数 | 价格 | 金额 | 交易后持股 | 申报 |
|---|---|---|---|---|---|---|---|
Culley Brian M President and CEO | Mar 12, 2026 | Purchase | 15,000 | $1.63 | $24.4K | 255.5K | Form 4 ↗ |
Culley Brian M President and CEO | Mar 5, 2026 | Award | 3,250,000 | $1.84 | $5.98M | 3.25M | Form 4 ↗ |
Howe Jill Ann Chief Financial Officer | Mar 5, 2026 | Award | 1,050,000 | $1.84 | $1.93M | 1.05M | Form 4 ↗ |
Samuel George A. III General Counsel and Secretary | Mar 5, 2026 | Award | 900,000 | $1.84 | $1.66M | 900.0K | Form 4 ↗ |
Culley Brian M President and CEO | Feb 11, 2026 | Tax Withhold | 12,869 | $1.80 | $23.2K | 240.5K | Form 4 ↗ |
Samuel George A. III General Counsel and Secretary | Feb 11, 2026 | Tax Withhold | 2,502 | $1.80 | $4.5K | 31.1K | Form 4 ↗ |
Culley Brian M President and CEO | Dec 19, 2025 | Award | 8,925 | — | — | 222.5K | Form 4 ↗ |
Culley Brian M President and CEO | Dec 19, 2025 | Tax Withhold | 334 | $1.68 | $561.12 | 222.1K | Form 4 ↗ |
Samuel George A. III General Counsel and Secretary | Dec 19, 2025 | Award | 1,735 | — | — | 27.6K | Form 4 ↗ |
Samuel George A. III General Counsel and Secretary | Dec 19, 2025 | Tax Withhold | 65 | $1.68 | $109.2 | 27.5K | Form 4 ↗ |
数据来源：SEC Form 4。买卖方向：acquisitionOrDisposition A=买入，D=卖出。已排除 RSU 归属（M-Exempt）。
关于机构与内部人持股结构
Lineage Cell Therapeutics, Inc.（LCTX）主要由机构投资者持有，机构持股比例约为 35.3%。公司内部人员持股约 5.12%，散户及公众持股约占剩余的 59.61%。
Lineage Cell Therapeutics, Inc. 最大机构股东为 BROADWOOD CAPITAL INC，截至 September 30, 2025 持有约 49.56 million 股，占总流通股的 21.70%。
目前共有 116 家机构持有 LCTX 股票，合计持仓市值约 $148,572,802，数据来源为最新 SEC 13F 申报。
常见问题
LCTX ownershipLineage Cell Therapeutics, Inc.（LCTX）主要由机构投资者持有，机构持股约 35.3%。最大股东为 BROADWOOD CAPITAL INC，持股比例 21.70%。内部人员持股约 5.12%。数据来源 SEC Form 13F，截至 September 30, 2025。